The most effective results of a combined anti-PD-1 and anti-CTLA4 immunotherapy was reported to be a 7-year intracranial progression-free survival in 42% of patients with active asymptomatic melanoma brain metastasis which appeared to keep the tumor under control rather than eliminating it [38]. The gene discussed is CTLA4; the disease is melanoma.